dc.contributor.author | Mantha, S | |
dc.contributor.author | Karp, Rebecca Sara | |
dc.contributor.author | Raghavan, V | |
dc.contributor.author | Terrin, N | |
dc.contributor.author | Bauer, Kenneth Alan | |
dc.contributor.author | Zwicker, Jeffrey Isaac | |
dc.date.accessioned | 2013-03-26T20:36:45Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Mantha, S, R Karp, V Raghavan, N Terrin, K A Bauer, and J I Zwicker. 2012. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. British Medical Journal 345:e4944. | en_US |
dc.identifier.issn | 0959-8138 | en_US |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:10466005 | |
dc.description.abstract | Objectives: To evaluate the risk of venous thromboembolic events associated with the use of progestin-only contraception and whether that risk differs with the mode of drug delivery (oral, intrauterine, or depot injection). Design: Systematic review and meta-analysis of randomised controlled trials and observational studies. Data sources: Pubmed, Embase, Cochrane Library, and reference lists of relevant reviews. Study selection: Randomised controlled trials and case-control, cohort, and cross sectional studies with venous thromboembolic outcome for progestin-only contraception reported relative to a non-hormone comparator group. Data extraction: Data were extracted by two independent investigators, and consensus for inclusion was reached after assessment by additional investigators. Results: Among the 2022 unique references identified by all searches, eight observational studies fulfilled inclusion criteria. A total of 147 women across all studies were diagnosed with a venous thromboembolic event while taking progestin-only contraception, and the summary measure for the adjusted relative risk of a venous thromboembolic episode for users versus non-users of a progestin-only contraceptive was, based on the random effects model, 1.03 (95% CI 0.76 to 1.39). Subgroup analysis confirmed there was no association between venous thromboembolic risk and progestin-only pills (relative risk 0.90 (0.57 to 1.45)) or a progestin intrauterine device (0.61 (0.24 to 1.53)). The relative risk of a venous thromboembolic event for users of an injectable progestin versus non-users was 2.67 (1.29 to 5.53). Conclusions: Published data assessing the risk of venous thromboembolism in women prescribed progestin-only contraception are limited. In this meta-analysis of eight observational studies, the use of progestin-only contraception was not associated with an increased risk of venous thromboembolism compared with non-users of hormonal contraception. The potential association between injectable progestins and thrombosis requires further study. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BMJ Publishing Group Ltd. | en_US |
dc.relation.isversionof | doi:10.1136/bmj.e4944 | en_US |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413580/pdf/ | en_US |
dash.license | LAA | |
dc.subject | Clinical Trials (Epidemiology) | en_US |
dc.subject | Contraception | en_US |
dc.subject | Drugs: Obstetrics and Gynaecology | en_US |
dc.subject | Reproductive Medicine | en_US |
dc.subject | Venous Thromboembolism | en_US |
dc.subject | Sexual Health | en_US |
dc.subject | Internet | en_US |
dc.title | Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis | en_US |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en_US |
dc.relation.journal | British Medical Journal | en_US |
dash.depositing.author | Bauer, Kenneth Alan | |
dc.date.available | 2013-03-26T20:36:45Z | |
dc.identifier.doi | 10.1136/bmj.e4944 | * |
dash.contributor.affiliated | Zwicker, Jeffrey | |
dash.contributor.affiliated | Bauer, Kenneth | |
dash.contributor.affiliated | Karp, Rebecca | |